AAPL338.30-6.34 (-1.84%) ▼|ABBV287.75-7.14 (-2.42%) ▼|ABT109.90+3.70 (+3.48%) ▲|ACN262.81+4.57 (+1.77%) ▲|ADBE255.00+4.77 (+1.91%) ▲|AMAT387.78-2.31 (-0.59%) ▼|AMD483.88-20.93 (-4.15%) ▼|AMGN466.59+0.58 (+0.12%) ▲|AMT188.18+0.40 (+0.21%) ▲|AMZN250.14+9.79 (+4.07%) ▲|AVGO329.94+3.86 (+1.18%) ▲|AXP328.87+9.76 (+3.06%) ▲|BA175.65+4.10 (+2.39%) ▲|BAC50.24+0.23 (+0.46%) ▲|BKNG155.04+6.91 (+4.66%) ▲|BLK1,174.62+27.08 (+2.36%) ▲|BMY62.46-0.02 (-0.03%) ▼|BNY148.30+1.19 (+0.81%) ▲|BRK-B554.76+12.27 (+2.26%) ▲|C123.82+1.85 (+1.52%) ▲|CAT623.25+0.50 (+0.08%) ▲|CL96.99+1.70 (+1.78%) ▲|CMCSA23.75+0.53 (+2.28%) ▲|COF212.07+7.22 (+3.52%) ▲|COP147.31-6.72 (-4.36%) ▼|COST1,039.22+26.94 (+2.66%) ▲|CRM232.27+3.10 (+1.35%) ▲|CSCO103.19-1.32 (-1.26%) ▼|CVS88.53-1.73 (-1.91%) ▼|CVX228.15-7.37 (-3.13%) ▼|DE664.40-11.08 (-1.64%) ▼|DHR229.50-2.73 (-1.18%) ▼|DIS113.60+2.66 (+2.40%) ▲|DUK127.93+0.54 (+0.42%) ▲|EMR168.41+3.47 (+2.10%) ▲|FDX319.72+6.44 (+2.06%) ▲|GD369.31-3.29 (-0.88%) ▼|GE315.95+14.15 (+4.69%) ▲|GEV877.20+19.33 (+2.25%) ▲|GILD170.19-0.49 (-0.29%) ▼|GM89.40+2.00 (+2.28%) ▲|GOOG281.97+3.75 (+1.35%) ▲|GOOGL283.48+3.64 (+1.30%) ▲|GS909.74+15.19 (+1.70%) ▲|HD339.46+10.26 (+3.12%) ▲|HON225.16+6.83 (+3.13%) ▲|IBM258.34+0.53 (+0.21%) ▲|INTC61.96-3.81 (-5.79%) ▼|INTU355.56+14.47 (+4.24%) ▲|ISRG444.94+12.93 (+2.99%) ▲|JNJ269.26-3.94 (-1.44%) ▼|JPM341.71+4.67 (+1.38%) ▲|KO95.69+1.61 (+1.71%) ▲|LIN521.96+7.72 (+1.50%) ▲|LLY1,412.61-4.93 (-0.35%) ▼|LMT641.11+4.16 (+0.65%) ▲|LOW216.26+7.19 (+3.44%) ▲|LRCX232.86-6.25 (-2.61%) ▼|MA659.63+21.62 (+3.39%) ▲|MCD263.87+5.75 (+2.23%) ▲|MDLZ66.05+1.11 (+1.70%) ▲|MDT98.69+2.15 (+2.23%) ▲|META612.09-2.90 (-0.47%) ▼|MMM179.35+5.01 (+2.87%) ▲|MO77.51-0.52 (-0.67%) ▼|MRK148.53-0.99 (-0.66%) ▼|MS186.52+2.22 (+1.20%) ▲|MSFT520.02-1.90 (-0.36%) ▼|MU852.74-32.00 (-3.62%) ▼|NEE84.99+1.28 (+1.52%) ▲|NFLX62.60+0.52 (+0.84%) ▲|NKE39.53+0.86 (+2.22%) ▲|NOW108.78+3.66 (+3.48%) ▲|NVDA206.58+1.94 (+0.95%) ▲|ORCL122.29-8.38 (-6.41%) ▼|PEP140.01+2.67 (+1.94%) ▲|PFE30.71+0.19 (+0.61%) ▲|PG163.79+2.22 (+1.37%) ▲|PLTR184.31+0.20 (+0.11%) ▲|PM208.04-0.75 (-0.36%) ▼|QCOM166.20+1.41 (+0.86%) ▲|RTX201.84+2.04 (+1.02%) ▲|SBUX103.86+0.21 (+0.20%) ▲|SCHW89.25+1.20 (+1.36%) ▲|SO94.31+0.60 (+0.64%) ▲|SPG222.83+5.08 (+2.33%) ▲|T21.44+0.03 (+0.14%) ▲|TMO685.44-11.56 (-1.66%) ▼|TMUS158.56+2.12 (+1.36%) ▲|TSLA408.55+8.74 (+2.18%) ▲|TXN308.30+7.46 (+2.48%) ▲|UBER67.19+1.94 (+2.97%) ▲|UNH397.41-9.57 (-2.35%) ▼|UNP307.49+3.49 (+1.15%) ▲|UPS109.57+1.32 (+1.22%) ▲|USB60.52+1.07 (+1.80%) ▲|V426.08+12.49 (+3.02%) ▲|VZ44.94+0.21 (+0.46%) ▲|WFC84.96+1.56 (+1.86%) ▲|WMT126.97+3.46 (+2.80%) ▲|XOM180.46-6.79 (-3.63%) ▼|AAPL338.30-6.34 (-1.84%) ▼|ABBV287.75-7.14 (-2.42%) ▼|ABT109.90+3.70 (+3.48%) ▲|ACN262.81+4.57 (+1.77%) ▲|ADBE255.00+4.77 (+1.91%) ▲|AMAT387.78-2.31 (-0.59%) ▼|AMD483.88-20.93 (-4.15%) ▼|AMGN466.59+0.58 (+0.12%) ▲|AMT188.18+0.40 (+0.21%) ▲|AMZN250.14+9.79 (+4.07%) ▲|AVGO329.94+3.86 (+1.18%) ▲|AXP328.87+9.76 (+3.06%) ▲|BA175.65+4.10 (+2.39%) ▲|BAC50.24+0.23 (+0.46%) ▲|BKNG155.04+6.91 (+4.66%) ▲|BLK1,174.62+27.08 (+2.36%) ▲|BMY62.46-0.02 (-0.03%) ▼|BNY148.30+1.19 (+0.81%) ▲|BRK-B554.76+12.27 (+2.26%) ▲|C123.82+1.85 (+1.52%) ▲|CAT623.25+0.50 (+0.08%) ▲|CL96.99+1.70 (+1.78%) ▲|CMCSA23.75+0.53 (+2.28%) ▲|COF212.07+7.22 (+3.52%) ▲|COP147.31-6.72 (-4.36%) ▼|COST1,039.22+26.94 (+2.66%) ▲|CRM232.27+3.10 (+1.35%) ▲|CSCO103.19-1.32 (-1.26%) ▼|CVS88.53-1.73 (-1.91%) ▼|CVX228.15-7.37 (-3.13%) ▼|DE664.40-11.08 (-1.64%) ▼|DHR229.50-2.73 (-1.18%) ▼|DIS113.60+2.66 (+2.40%) ▲|DUK127.93+0.54 (+0.42%) ▲|EMR168.41+3.47 (+2.10%) ▲|FDX319.72+6.44 (+2.06%) ▲|GD369.31-3.29 (-0.88%) ▼|GE315.95+14.15 (+4.69%) ▲|GEV877.20+19.33 (+2.25%) ▲|GILD170.19-0.49 (-0.29%) ▼|GM89.40+2.00 (+2.28%) ▲|GOOG281.97+3.75 (+1.35%) ▲|GOOGL283.48+3.64 (+1.30%) ▲|GS909.74+15.19 (+1.70%) ▲|HD339.46+10.26 (+3.12%) ▲|HON225.16+6.83 (+3.13%) ▲|IBM258.34+0.53 (+0.21%) ▲|INTC61.96-3.81 (-5.79%) ▼|INTU355.56+14.47 (+4.24%) ▲|ISRG444.94+12.93 (+2.99%) ▲|JNJ269.26-3.94 (-1.44%) ▼|JPM341.71+4.67 (+1.38%) ▲|KO95.69+1.61 (+1.71%) ▲|LIN521.96+7.72 (+1.50%) ▲|LLY1,412.61-4.93 (-0.35%) ▼|LMT641.11+4.16 (+0.65%) ▲|LOW216.26+7.19 (+3.44%) ▲|LRCX232.86-6.25 (-2.61%) ▼|MA659.63+21.62 (+3.39%) ▲|MCD263.87+5.75 (+2.23%) ▲|MDLZ66.05+1.11 (+1.70%) ▲|MDT98.69+2.15 (+2.23%) ▲|META612.09-2.90 (-0.47%) ▼|MMM179.35+5.01 (+2.87%) ▲|MO77.51-0.52 (-0.67%) ▼|MRK148.53-0.99 (-0.66%) ▼|MS186.52+2.22 (+1.20%) ▲|MSFT520.02-1.90 (-0.36%) ▼|MU852.74-32.00 (-3.62%) ▼|NEE84.99+1.28 (+1.52%) ▲|NFLX62.60+0.52 (+0.84%) ▲|NKE39.53+0.86 (+2.22%) ▲|NOW108.78+3.66 (+3.48%) ▲|NVDA206.58+1.94 (+0.95%) ▲|ORCL122.29-8.38 (-6.41%) ▼|PEP140.01+2.67 (+1.94%) ▲|PFE30.71+0.19 (+0.61%) ▲|PG163.79+2.22 (+1.37%) ▲|PLTR184.31+0.20 (+0.11%) ▲|PM208.04-0.75 (-0.36%) ▼|QCOM166.20+1.41 (+0.86%) ▲|RTX201.84+2.04 (+1.02%) ▲|SBUX103.86+0.21 (+0.20%) ▲|SCHW89.25+1.20 (+1.36%) ▲|SO94.31+0.60 (+0.64%) ▲|SPG222.83+5.08 (+2.33%) ▲|T21.44+0.03 (+0.14%) ▲|TMO685.44-11.56 (-1.66%) ▼|TMUS158.56+2.12 (+1.36%) ▲|TSLA408.55+8.74 (+2.18%) ▲|TXN308.30+7.46 (+2.48%) ▲|UBER67.19+1.94 (+2.97%) ▲|UNH397.41-9.57 (-2.35%) ▼|UNP307.49+3.49 (+1.15%) ▲|UPS109.57+1.32 (+1.22%) ▲|USB60.52+1.07 (+1.80%) ▲|V426.08+12.49 (+3.02%) ▲|VZ44.94+0.21 (+0.46%) ▲|WFC84.96+1.56 (+1.86%) ▲|WMT126.97+3.46 (+2.80%) ▲|XOM180.46-6.79 (-3.63%) ▼|
19.6 C
New York
Monday, November 2, 2026

Tag: management

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company’s previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (“HyalRoute”) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an “AI infrastructure network powered by optical technologies” and an “AI application services matrix.”

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Global Rise in Delayed Childbearing and Infertility Drives Demand for Cross-Border Fertility Care

Asian Case Studies Highlight How Regulation, Cost, and Access Are Shaping International Family ChoicesTAIPEI, June 6, 2026 /PRNewswire/ -- Delayed marriage, postponed childbearing, and...

Inturai Ventures Announces Adoption of Semi-Annual Reporting

(CSE: URAI  / OTC: URAIF / FSE: 3QG0)                                                                                                    investor@inturai.comVANCOUVER, BC, June 5, 2026 /CNW/ - Inturai Ventures Corp. (CSE: URAI) (OTC: URAIF) (FSE: 3QG0) (the...

JEF INVESTIGATION: Robbins Geller Rudman & Dowd LLP Launches Investigation into Jefferies Financial Group, Inc. and Encourages Investors and Potential Witnesses to Contact Law...

We are investigating whether Jefferies Financial Group Inc. & certain of its top executives made materially false &/or misleading statements to investors.

InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering

New York, NY, June 05, 2026 (GLOBE NEWSWIRE) -- InterPrivate Investment Partners V, Inc. (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced the closing of its initial public offering of 20,125,000 units, including 2,625,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, at a price of $10.00 per unit on June 5, 2026. Total gross proceeds from the offering were $201.25 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

ELWT Investor News: If You Have Suffered Losses in Elauwit Connection, Inc. (NASDAQ: ELWT), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Elauwit Connection, Inc. (NASDAQ: ELWT) resulting from allegations that Elauwit may have issued materially misleading business information to the investing public.

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsManagement